Actively Recruiting
Clinical Study Evaluating Safety, Tolerability, and Immune Response of Variant-Adapted BNT162b2 COVID-19 Vaccines in Children and Adults
Led by BioNTech SE · Updated on 2026-09-28
700
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of updated COVID-19 vaccines called BNT162b2 in people aged 5 to 64 years who have risk factors for severe COVID-19 and in those aged 65 years and older. This Phase 3 study aims to understand how these vaccines work for prevention and to assess their tolerability and immune response. Participants must be medically stable and have no recent COVID-19 infection or vaccination. Participants in Cohort 1 receive a single age-appropriate dose of BNT162b2 vaccine targeting the 20262027 recommended COVID-19 strain, with doses of 30 mcg for those 12 years and older and 10 mcg for children 5 to 11 years old. Cohort 2 participants are randomly assigned to receive one injection of one of three variant-adapted BNT162b2 vaccines. All injections are given in the upper arm and participants and study staff are blinded in Cohort 2. The study lasts about 6 months with at least three visits. Participants track side effects and complete diaries after visits. For Cohort 1, nose swabs and blood samples are taken at two visits, while for Cohort 2 these samples are collected at every visit. Researchers measure local and systemic reactions, adverse events, serious adverse events, and immune responses such as geometric mean fold rise and seroresponse to evaluate vaccine safety and effects over time.
CONDITIONS
Brief Title
A Study of COVID-19 Vaccine(s) in Children and Adults
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here